Status:
COMPLETED
Treatment of Primary CNS Lymphoma ( FTD )
Lead Sponsor:
Mingzhi Zhang
Collaborating Sponsors:
Zhengzhou University
Conditions:
Primary CNS Lymphoma (PCNSL)
Eligibility:
All Genders
14-69 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of FTD regiment (fotemustine, temozolomide and dexamethasone ) for patients with primary CNS lymphoma.
Detailed Description
Primary CNS lymphoma (PCNSL) is a rare B-cell variant of non-Hodgkin lymphoma that is confined to the brain, leptomeninges, spinal cord, and eyes. The optimum treatment for patients with PCNSL remains...
Eligibility Criteria
Inclusion
- Age range 14-69 years old;KPS performance status≥60 or ECOG performance status 0-2; Estimated survival time \> 3 months; Histological confirmed PCNSL; None of chemotherapy contraindication;At least one measurable lesion according to RECIST;None of other serious diseases;Patients could be followed up;None of other relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
- volunteers who signed informed consent.
Exclusion
- Currently undergoing chemotherapy, radiotherapy and targeted therapy (received chemotherapy within 3 weeks, received radiotherapy within 2 weeks, or has not recovered from any previous treatment of acute toxicity);Patients with uncontrolled medical problems (including active infection, uncontrolled diabetes, severe heart, liver, kidney dysfunction and interstitial pneumonia, etc.); Pregnant or lactating women;Serious medical illness likely to interfere with participation;Chemotherapy contraindication such as cachexia; patients with other malignancies previously;Serious infection;The evidence of peripheral nervous disorder or dysphrenia; patients estimated to be unsuitable by investigato
Key Trial Info
Start Date :
March 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 2 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05274139
Start Date
March 2 2017
End Date
March 2 2019
Last Update
March 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Department of The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052